Published in Oncoimmunology on May 27, 2015
Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma. Cancer Res (2016) 0.75
Regulatory T cells in tumor immunity. Int J Cancer (2010) 4.53
Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol (2011) 4.29
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 4.07
Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol (2006) 3.28
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
Melanoma: from mutations to medicine. Genes Dev (2012) 2.59
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43
Antioxidants accelerate lung cancer progression in mice. Sci Transl Med (2014) 2.23
Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med (2003) 1.92
Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol (2013) 1.70
Regulatory T cells in nonlymphoid tissues. Nat Immunol (2013) 1.69
Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol (2007) 1.59
Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol (2013) 1.53
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol (2007) 1.52
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res (2009) 1.52
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood (2011) 1.51
TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol (2008) 1.49
The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res (2003) 1.47
Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res (2001) 1.46
CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res (2011) 1.42
Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid Redox Signal (2012) 1.36
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol (2012) 1.34
High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res (2005) 1.28
Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol (2012) 1.23
The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal (2013) 1.20
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest (2014) 1.12
Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res (2006) 0.96
The tumor microenvironment: characterization, redox considerations, and novel approaches for reactive oxygen species-targeted gene therapy. Antioxid Redox Signal (2012) 0.86
Measurement of reactive oxygen species in the culture media using Acridan Lumigen PS-3 assay. J Biomol Tech (2011) 0.84
Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2. Scand J Immunol (2011) 0.81
FOXP3 regulates sensitivity of cancer cells to irradiation by transcriptional repression of BRCA1. Cancer Res (2013) 0.80
Immunotherapy for malignant melanoma. Curr Stem Cell Res Ther (2012) 0.79